JPRN-jRCT2071230058已完成1 期
Investigation of safety, tolerability and pharmacokinetic properties of multiple doses of oral NNC0487-0111 in Japanese participants with obesity(NN9487-5022)
Sudoh Yuki0 个研究点目标入组 36 人开始时间: 2023年9月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 55age old（—）
- 性别
- Male
入选标准
- •Male with both parents of Japanese descent
- •-Body mass index (BMI) between 25.0 and 34.9 kg/m2 (both inclusive). Body weight >=65.0 kg
- •-Considered eligible based on the medical history, physical examination, and the results of vital
- •signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening
- •visit, as judged by the investigator
排除标准
- •-Any disorder that in the opinion from investigators might jeopardise participants safety or
- •compliance with the protocol
- •-Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal
- •disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator
研究者
相似试验
已完成
1 期
Investigation of safety, tolerability and pharmacokinetic properties of single subcutaneous doses of NNC0194-0499 in Japanese and non-Asian male subjectsnon-alcoholic steatohepatitisJPRN-jRCT2071200100Sudoh Yuki42
已完成
不适用
Investigation of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of NNC0480-0389 in combination with semaglutide s.c.diabetesNL-OMON55332ovo Nordisk156
招募中
不适用
A study to explore the safety, tolerability, pharmacokinetic profile, and potential efficacy of Guanabenz in patients with early childhood onset Vanishing White Matter (VWM)CACH1002929910012303NL-OMON55425Vrije Universiteit Medisch Centrum40
招募中
不适用
Guanabenz in VWMVanishing White Matter (VWM)Childhood ataxia with central nervous system hypomyelination (CACH)NL-OMON24121Amsterdam University Medical Centers, location VUmc, De Boelelaan 1117, 1081HV Amsterdam30
进行中（未招募）
1 期
Pediatric PK Study (POS IV and PFS)Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia.EUCTR2014-002807-10-CZMerck Sharp & Dohme Corp.84